Clinical Scorecard: Prognostic Impact of Surgical Resection at Initial Recurrence in IDH-Mutant Lower-Grade Gliomas: Findings from a Retrospective Volumetric Study at a Single Institution

At a Glance

Key Highlights

• Early maximal safe resection at initial diagnosis is a cornerstone for long-term tumor control in IDHmut lower-grade gliomas.
• Repeat resection at first recurrence may alleviate symptoms, assess malignant transformation, and guide molecularly-informed treatment.
• Survival benefit of repeat resection at recurrence remains debated; prior studies lacked comprehensive molecular and volumetric assessment.

Guideline-Based Recommendations

Diagnosis

• Neuropathological diagnosis requires combined histological and molecular markers per WHO CNS 5 classification.
• Confirmed IDH mutation and subtype-defining molecular markers are prerequisites for diagnosis.
• Exclude astrocytoma patients with CDKN2A/B homozygous deletion due to poor prognosis.

Management

• At initial diagnosis, maximal safe surgical resection is recommended for tumor control.
• At first recurrence, treatment should be individualized based on clinical condition, tumor characteristics, and prior treatments.
• Repeat resection offers symptom relief and molecular reassessment but lacks definitive evidence for survival benefit.
• Non-surgical options include radiotherapy and systemic treatments.

Monitoring & Follow-up

• Use standardized MRI protocols including FLAIR, T2, and T1 sequences pre- and post-operatively.
• Volumetric assessment of tumor and residual tumor volume (RTV) is important for evaluating extent of resection.
• Follow-up should include clinical and radiographic evaluation for progression-free survival and survival after recurrence.

Risks

• Potential surgical complications and functional outcomes should be carefully evaluated when considering repeat resection.
• Long-term survival and evolving treatment paradigms introduce bias in outcome assessment.

Patient & Prescribing Data

148 patients with radiographically confirmed first recurrence of IDHmut astrocytoma or oligodendroglioma, WHO grade 2 or 3

33.8% underwent repeat resection at first recurrence; majority had high functional status (median KPS 90) and were neurologically intact prior to treatment

Clinical Best Practices

• Perform comprehensive molecular characterization including IDH mutation and 1p/19q co-deletion status for accurate diagnosis.
• Aim for maximal safe resection at initial diagnosis to improve long-term tumor control.
• Consider repeat resection at first recurrence for symptom relief and molecular reassessment, weighing potential benefits against surgical risks.
• Utilize volumetric MRI analysis to quantify extent of resection and residual tumor volume.
• Tailor treatment strategies at recurrence based on patient clinical status, tumor characteristics, and prior therapies.
• Monitor patients closely with standardized imaging and clinical assessments to guide further management.

References

• WHO CNS 5 Classification
• Joint Tumor Section Guidelines on Surgery for Recurrent Glioma WHO Grade 2
• RANO Criteria for Glioma Assessment